Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
about
Fifty years of melphalan use in hematopoietic stem cell transplantationAllogeneic hematopoietic cell transplantation in patients with AML not achieving remission: potentially curative therapy.Reduced-intensity conditioning transplantation in acute leukemia: the effect of source of unrelated donor stem cells on outcomes.Design of a cost-effectiveness analysis alongside a randomized trial of transplantation using umbilical cord blood versus HLA-haploidentical related bone marrow in advanced hematologic cancerLeukemia burden delays lymphocyte and platelet recovery after allo-SCT for AML.Reduced-intensity conditioning followed by related allografts in hematologic malignancies: long-term outcomes most successful in indolent and aggressive non-Hodgkin lymphomasFactors predicting long-term survival after T-cell depleted reduced intensity allogeneic stem cell transplantation for acute myeloid leukemia.Conditioning regimens for hematopoietic cell transplantation: one size does not fit allEffect of conditioning regimen intensity on acute myeloid leukemia outcomes after umbilical cord blood transplantationMulticenter biologic assignment trial comparing reduced-intensity allogeneic hematopoietic cell transplant to hypomethylating therapy or best supportive care in patients aged 50 to 75 with intermediate-2 and high-risk myelodysplastic syndrome: BloodLong-term outcome of reduced-intensity allogeneic hematopoietic SCT in patients with AML in CRAlternative donor transplantation after reduced intensity conditioning: results of parallel phase 2 trials using partially HLA-mismatched related bone marrow or unrelated double umbilical cord blood grafts.Similar transplantation outcomes for acute myeloid leukemia and myelodysplastic syndrome patients with haploidentical versus 10/10 human leukocyte antigen-matched unrelated and related donors.Fludarabine-melphalan conditioning for AML and MDS: alemtuzumab reduces acute and chronic GVHD without affecting long-term outcomes.Allogeneic haematopoietic cell transplantation for myelofibrosis in 30 patients 60-78 years of age.Response to pneumococcal (PNCRM7) and haemophilus influenzae conjugate vaccines (HIB) in pediatric and adult recipients of an allogeneic hematopoietic cell transplantation (alloHCT)Umbilical cord blood transplantation after nonmyeloablative conditioning: impact on transplantation outcomes in 110 adults with hematologic disease.Current status of allogeneic hematopoietic cell transplantation for MDS.Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplantation for adult patients with myelodysplastic syndrome and myeloproliferative disorders.Clinical outcomes of AML patients relapsing after matched-related donor and umbilical cord blood transplantation.Double umbilical cord blood transplantation in patients with hematologic malignancies using a reduced-intensity preparative regimen without antithymocyte globulin.Hematopoietic transplantation from adult unrelated donors as treatment for acute myeloid leukemia.Reduced-intensity conditioning and allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia.Myeloablative allogeneic bone marrow transplant using T cell depleted allografts followed by post-transplant GM-CSF in high-risk myelodysplastic syndromes.TLI and ATG conditioning with low risk of graft-versus-host disease retains antitumor reactions after allogeneic hematopoietic cell transplantation from related and unrelated donors.The evolution of hematopoietic SCT in myelodysplastic syndrome.A 5-day cytoreductive chemotherapy followed by haplo-identical hsct (FA5-BUCY) as a tumor-ablative regimen improved the survival of patients with advanced hematological malignancies.Treosulfan, fludarabine, and 2-Gy total body irradiation followed by allogeneic hematopoietic cell transplantation in patients with myelodysplastic syndrome and acute myeloid leukemia.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.To transplant or not: a dilemma for treatment of elderly AML patients in the twenty-first century.Treatment of older patients with high-risk myelodysplastic syndromes (MDS): the emerging role of allogeneic hematopoietic stem cell transplantation (Allo HSCT).Reduced intensity conditioning for allogeneic hematopoietic cell transplantation: considerations for evidence-based GVHD prophylaxis.Reduced-intensity conditioned allogeneic SCT in adults with AML.Cytogenetics and comorbidity predict outcomes in older myelodysplastic syndrome patients after allogeneic stem cell transplantation using reduced intensity conditioning.Clinical activity of laromustine (Onrigin™) in hematologic malignancies.CD34+ cell dose and establishment of full donor chimerism at day +100 are important factors for survival with reduced-intensity conditioning with fludarabine and melphalan before allogeneic hematopoietic SCT for hematologic malignancies.Feasibility of clofarabine cytoreduction before allogeneic transplant conditioning for refractory AML.Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.Fludarabine Melphalan reduced-intensity conditioning allotransplanation provides similar disease control in lymphoid and myeloid malignancies: analysis of 344 patients.
P2860
Q26824498-BECB782F-8B70-40DE-8357-698476739BA0Q30399209-2065FD48-624B-4385-ACD2-192967D1D596Q30418861-2829807D-7C73-4907-A2E0-A0320563702FQ33677912-ED32CF4A-B493-4EB7-B3D0-F68AECC4992EQ33684432-F33A1490-8FA8-4967-A649-8DACB60B8A64Q33850163-0CA9B968-6089-4381-A3DA-BC78B145394AQ33886217-FD40C5BA-1195-452F-A653-342DC0CFE3F1Q33917170-70E68C9F-E575-4571-B14D-F844C8DE9C91Q34033553-C91918C6-B02A-41ED-89C5-C755D12FAB9AQ34217884-28C48DC6-5C21-4CC6-811F-CDBF9895A410Q35060676-6002F0FB-74B8-4EC3-BEDA-E20CBA103A21Q35112222-E52C75A9-3378-4305-B036-BACD4CC4E47BQ35129248-B2D7A3F5-A961-488F-81E2-0FFEAE85589EQ35142616-3208A0F8-369B-4263-BB93-A96ABEA90EF9Q35608022-17171A23-7150-4C48-9097-75325D63B203Q35623591-9A103B6E-C5C9-42E7-8036-0043942340EAQ36059652-42332B94-793B-4BE2-BDF6-9D8BCAD1D955Q36063049-968A119E-204B-41CB-860C-F5A6B77DB741Q36484688-1F645E69-3C4A-4713-B736-9BBEA33EEB40Q36623397-A61F5B39-7AE7-483E-BF8B-158A0717094CQ36923436-B4682F26-DB9E-41D9-B050-E85729FF45D4Q37061969-07EB1802-20B3-4277-91AF-D60E06D7F788Q37159533-A4213558-9574-455F-AD40-9B7D20F310FEQ37286248-24D92240-A154-4E93-8DE1-7ADBCE8B5A94Q37291642-451F5F7E-9BED-45E6-BD2F-00C06E8E6DABQ37404489-C3C73797-63B6-4389-8E20-7D5834B0C618Q37694704-B4785505-7BE5-460D-9057-A64EC007A82CQ37718826-DC536F05-A61D-40E4-AABD-ED240B73F3E2Q38029953-B4E03F30-360B-49BC-88B4-E57EB0C676D4Q38095833-DF856976-F689-4BFF-A92D-3AFA9F7B5AF1Q38104287-5E6594FA-F956-4B21-988A-C9E32BA6AEE9Q38176519-6FE35A16-5BE9-4596-B14B-2539DFF2D2B3Q38202155-4CCB447E-9471-4C1E-A883-D25B306C509EQ38366632-9568D849-58BF-4453-87D1-ECF609E8298AQ40282393-751C4CBD-5D52-48EF-97CC-79ED6329618BQ42807419-A6AD2BAE-D6A5-4416-B2E5-2F33231E86A1Q43140217-123700CE-EC48-49BE-8451-0F89BD79F1D2Q43140221-9DBC0E25-B9E8-47BA-8A87-803042A964A6Q43198291-B7A74685-7DD4-43D7-A8E2-AEACAD587F44Q44477117-9DF67DDA-3A19-45DB-B9A4-2E36C5132495
P2860
Allogeneic hematopoietic stem cell transplantation for the treatment of high-risk acute myelogenous leukemia and myelodysplastic syndrome using reduced-intensity conditioning with fludarabine and melphalan.
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@ast
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@en
type
label
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@ast
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@en
prefLabel
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@ast
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@en
P2093
P2860
P1476
Allogeneic hematopoietic stem ...... ith fludarabine and melphalan.
@en
P2093
Antonio Carrasco-Yalan
Athanasios Anagnostopoulos
Betul Oran
Chitra Hosing
Daniel Couriel
Ernesto de Meis
Issa Khouri
Marcos de Lima
Michele Donato
Muzaffar Qazilbash
P2860
P304
P356
10.1016/J.BBMT.2006.11.024
P577
2007-02-08T00:00:00Z